University of California Davis Health
Welcome,         Profile    Billing    Logout  
 40 Trials 
53 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bowlus, Christopher L
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd., ChemomAb Ltd
Primary Sclerosing Cholangitis
09/24
09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Not yet recruiting
2
87
US
LB-P8 low-dose, LB-P8 high-dose, Placebo
LISCure Biosciences
Primary Sclerosing Cholangitis (PSC)
03/28
02/29
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
Sood, Namita
ARTISAN, NCT05203510: A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Recruiting
4
50
US
Parenteral Treprostinil, Remodulin, Oral Treprostinil, Orenitram
United Therapeutics, Lung Biotechnology PBC
Pulmonary Arterial Hypertension
12/25
12/27
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Terminated
3
186
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
08/24
08/24
NCT05983250: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Recruiting
3
152
Canada, US
TNX-103, Placebo
Tenax Therapeutics, Inc., Medpace, Inc., Northwestern University
Pulmonary Hypertension
03/27
07/27
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
ASCENT, NCT06129240: An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Recruiting
N/A
60
US
LIQ861
Liquidia Technologies, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
07/26
10/26
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Checkmark
Oct 2015 - Oct 2015: 
Recruiting
N/A
3000
US
Duke University, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
01/28
01/28
Abedi, Mehrdad
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/25
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
Starlight-1, NCT06343311: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Recruiting
1/2
21
US
EB103
Estrella Biopharma, Inc., Eureka Therapeutics Inc.
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/26
12/27
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Hourglass Jul 2024 - Dec 2024 : Submission in UK for adult r/r B-ALL
Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
LIMBER-TREG108, NCT05423691: Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Recruiting
1
24
US
CK0804
Cellenkos, Inc.
Myelofibrosis
04/24
04/24
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Recruiting
1
186
US
OrcaGraft (Orca-Q)
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
04/26
04/28
NEXICART-2, NCT06097832: Study of NXC-201 CAR-T in Patients with Light Chain (AL) Amyloidosis

Recruiting
1
40
US
NXC-201 CAR-T, HBI0101 CAR-T
Nexcella Inc., Immix Biopharma, Inc.
Light Chain (AL) Amyloidosis
12/26
01/39
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting
1
55
US
DSG3-CAART or CABA-201
Cabaletta Bio
Pemphigus Vulgaris
01/29
01/29
Painting, Lynda
GuideView, NCT04838626 / 2020-003958-67: Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Completed
2/3
195
Europe, US
[18F]CTT1057, Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
Novartis Pharmaceuticals
Prostatic Neoplasms, Prostate Cancer
11/23
11/23
Dhaliwal, Sandeep
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
GATEWAY, NCT04537377 / 2020-000963-22: A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

Active, not recruiting
1/2
4
Europe, US
VTX-801
Vivet Therapeutics SAS
Wilson's Disease
12/24
06/29
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
TARGET-IBD, NCT03251118: A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Recruiting
N/A
15000
US
Target PharmaSolutions, Inc.
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
10/25
10/25
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Recruiting
N/A
15000
Europe, US
Target PharmaSolutions, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
07/36
07/36
Cohen, Stuart
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting
3
274
Europe, US, RoW
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Ansun Biopharma, Inc.
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
08/25
08/25
Diebel, Elizabeth
NCT03904147: TRILUMINATE Pivotal Trial

Active, not recruiting
N/A
572
Europe, Canada, US
TriClipTM Device
Abbott Medical Devices
Tricuspid Regurgitation
11/22
04/29
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
Nardo, Lorenzo
GuidePath, NCT04838613 / 2020-003959-16: Study of Diagnostic Performance of [18F]CTT1057 in BCR

Completed
3
180
Europe, US
[18F]CTT1057, [68Ga]Ga-PSMA-11
Novartis Pharmaceuticals, Novartis Pharma AG
Prostatic Neoplasms, Prostate Cancer, Recurrence
11/23
11/23
GuideView, NCT04838626 / 2020-003958-67: Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Completed
2/3
195
Europe, US
[18F]CTT1057, Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
Novartis Pharmaceuticals
Prostatic Neoplasms, Prostate Cancer
11/23
11/23
EXPLLN21-01, NCT05160480: A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Enrolling by invitation
N/A
9
US
Total-body PET imaging
University of California, Davis, Lantheus Medical Imaging
Prostate Cancer, Breast Cancer, Neuroendocrine Tumors
09/25
03/26
Gutierrez, Haydee
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
Nguyen, Jessica N
HEALICOIL_KNTL, NCT04552119: Safety of Treatment of Shoulder Repair

Active, not recruiting
N/A
160
US
HEALICOIL Knotless PEEK, HEALICOIL Knotless REGENESORB
Smith & Nephew, Inc.
Rotator Cuff
08/24
12/24
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
Golez, Jerica
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis

Recruiting
3
150
US, RoW
Saroglitazar Magnesium 1 mg
Zydus Therapeutics Inc.
Primary Biliary Cholangitis
04/27
07/27
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
Oyegbile-Chidi, Temitayo
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
Thai, Chinh
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
Husen, Lilian Von
NCT06131203: Burn Validation Study

Recruiting
N/A
240
US
DeepView SnapShot Portable (DV-SSP)
SpectralMD
Burns, Wound Heal, Wounds and Injuries
03/25
04/25
Hojman, Nayla
NCT06131203: Burn Validation Study

Recruiting
N/A
240
US
DeepView SnapShot Portable (DV-SSP)
SpectralMD
Burns, Wound Heal, Wounds and Injuries
03/25
04/25
Amezcua
No trials found
Lum, Zachary C
No trials found
Dallas-Orr, David
No trials found

Download Options